Prognostic factors in resected stage I non–small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival  by Hung, Jung-Jyh et al.
P
c
i
J
a
General Thoracic Surgery Hung et al
6
G
TSrognostic factors in resected stage I non–small cell lung
ancer with a diameter of 3 cm or less: Visceral pleural
nvasion did not influence overall and disease-free survival
ung-Jyh Hung, MD,a,b Chien-Ying Wang, MD,b Min-Hsiung Huang, MD,b Biing-Shiung Huang, MD,b Wen-Hu Hsu, MD,b,*
nd Yu-Chung Wu, MDb,*
O
c
I
(
o
n
M
p
l
D
R
T
T
s
.
r
o
C
d
i
t
p
L
a
c
r
(
e
t
d
S
w
s
rFrom the Institute of Clinical Medicine,
National Yang-Ming University,a Taipei,
Taiwan; and the Division of Thoracic Sur-
gery, Department of Surgery, Taipei Veter-
ans General Hospital and School of Medi-
cine,b National Yang-Ming University,
Taipei, Taiwan.
Received for publication Dec 12, 2006; re-
visions received April 5, 2007; accepted for
publication April 11, 2007.
Address for reprints: Yu-Chung Wu, MD,
No. 201, Section 2, Shih-Pai Road, Divi-
sion of Thoracic Surgery, Department of
Surgery, Taipei Veterans General Hospital,
Taipei 112, Taiwan (E-mail: wuyc@vghtpe.
gov.tw).
*Drs Wen-Hu Hsu and Yu-Chung Wu con-
tributed equally to this article.
J Thorac Cardiovasc Surg 2007;134:638-43
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgery
Drs Wu, Hsu, and Hung (left to right)i
doi:10.1016/j.jtcvs.2007.04.059
38 The Journal of Thoracic and Cardiobjective: Resection is the treatment of choice for patients with stage I non–small
ell lung cancer. Stage I non–small cell lung cancer has been further subdivided into
A (T1N0M0, tumor size  3 cm without visceral pleural invasion) and IB
T2N0M0, tumor size  3 cm or any size with visceral pleural invasion). The aim
f this study was to evaluate the prognostic factors in patients with resected stage I
on–small cell lung cancer with a diameter of 3 cm or less.
ethods: We retrospectively reviewed the clinicopathologic characteristics of 445
atients with resected stage I non–small cell lung cancer with a diameter of 3 cm or
ess who were treated at Taipei Veterans General Hospital between 1980 and 2000.
isease-free survival, overall survival, and their predictors were analyzed.
esults: The 5- and 10-year overall survivals were 61.4% and 40.0%, respectively.
he 5- and 10-year disease-free survivals were 74.5% and 73.4%, respectively.
umor size, smoking index, and number of mediastinal lymph nodes dissected were
ignificant predictors for both disease-free survival (P  .009, P  .002, and P 
006, respectively) and overall survival (P  .004, P  .001, and P  .001,
espectively) in multivariate analyses. Visceral pleural invasion did not influence
verall survival or disease-free survival.
onclusions: Tumor size, smoking index, and number of mediastinal lymph nodes
issected were prognostic factors for both overall survival and disease-free survival
n resected stage I non–small cell lung cancer with a diameter of 3 cm or less. Small
umors (3 cm) of stage IB (T2N0M0) non–small cell lung cancer with visceral
leural invasion should be treated as T1 disease and not T2 disease.
ung cancer is a prevalent health problem worldwide. It is the leading cause
of cancer death in both men and women in the United States. In Taiwan, it
is also the most common cause of death related to malignancy for women
nd the second most common cause of death for men.1 Optimal management of lung
ancer depends on proper histologic identification and tumor staging. Surgical
esection is the treatment of choice for early-stage non–small cell lung cancer
NSCLC).2
The importance of tumor staging on survival for patients with NSCLC has been
mphasized. Patients with stage I disease have the most favorable prognosis and are
reated with surgical resection. However, survival varies according to reports from
ifferent centers.2-5 Five-year survival after resection ranges between 55% and 80%.
tage I NSCLC has been further subdivided into IA (T1N0M0, tumor size  3 cm
ithout visceral pleural invasion [VPI]) and IB (T2N0M0, tumor size 3 cm or any
ize with VPI).3 The 5-year survival of patients with resected stage IA NSCLC
anges from 62% to 82%.6-9 VPI has been reported as a significant negative
ndicator of survival in patients who underwent complete resection of NSCLC.10-13
vascular Surgery ● September 2007
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TShe classification of VPI by the Japan Lung Cancer Society
s as follows: p0, tumor with no pleural involvement beyond
ts elastic layer; p1, tumor that extends beyond the elastic
ayer of the visceral pleura but is not exposed on the pleural
urface; p2, tumor that is exposed on the pleural surface but
oes not involve adjacent anatomic structures; and p3, tu-
or that involves adjacent anatomic structures.14 For re-
ected NSCLC with a diameter of 3 cm or less, Shimizu and
olleagues13 reported that 5-year survivals for patients with
1 or p2 tumors were identical to and significantly worse
han survivals of those with p0 tumors. For resected NSCLC
ith a diameter of 2 cm or less, Inoue and colleagues15
eported that lymph node metastasis was significantly in-
reased in patients with VPI. However, the prognostic value
f VPI in patients with early-stage NSCLC (T1–2N0M0)
ith a small tumor size has rarely been demonstrated.
Although the prognosis of stage IA NSCLC is relatively
ood compared with that of more advanced stages,6-9,16 the
utcome of stage I NSCLC with a diameter of 3 cm or less
fter surgical resection has rarely been reported. In this
eport, we analyzed the survival and prognostic factors in
tage I NSCLC with a diameter of 3 cm or less after surgical
esection.
aterials and Methods
rom January 1980 to December 2000, 970 patients underwent
urgical resection for pathologic stage I NSCLC (T1N0M0 and
2N0M0) at Taipei Veterans General Hospital. The preoperative
taging workup included serum biochemistry tests, chest and upper
bdomen computed tomographic scans, bronchoscopic examina-
ion, and nuclear medicine survey (bone and brain). Mediastinos-
opy was not a routine procedure in the preoperative staging
orkup unless enlarged lymph nodes (diameter  1.0 cm) were
bserved on the contralateral side of the mediastinum from the
omputed tomography scan. Patients with suspected distant me-
astasis were excluded from consideration of operation. A complete
esection of all disease in the lung with mediastinal lymph node
issection was performed as previously described.17 Pathologic stag-
ng was assessed after examination of the resected specimens had
een performed and all regional nodes had been dissected. The
urgical and pathologic reports of all patients were reviewed to ensure
ccurate staging was performed, complete resection was achieved,
nd no regional nodes (N1 and N2) were involved. Histologic typing
as determined according to the World Health Organization classi-
cation.18 Determination of disease stages were based on the TNM
lassification of the International Union Against Cancer.19 All pa-
ients were followed up at our outpatient department quarterly in
he first 2 years after resection and semiannually thereafter.
Of these 970 patients with a final pathologic stage defined as
Abbreviations and Acronyms
NSCLC non–small cell lung cancer
VPI  visceral pleural invasiontage I (T1N0M0 and T2N0M0), 445 (45.9%) had tumors with a d
The Journal of Thoraciciameter of 3 cm or less, and they formed the samples for this
eview. The characteristics of these 445 patients are listed in Table
. To investigate their impact on disease-free survival and overall
urvival, the following clinicopathologic factors were used in
nivariate and multivariate analyses: age, gender, smoking index,
aterality of tumor (right vs left), histologic type of the tumor
squamous cell carcinoma vs others), tumor size, extent of resec-
ion (pneumonectomy or bilobectomy vs lobectomy or wedge
esection), VPI (present vs absent), number of mediastinal lymph
odes dissected (15 vs15), number of mediastinal lymph node
tations dissected (3 vs 3), lymphatic invasion (present vs
bsent), and vascular invasion (present vs absent). The length of
urvival was defined as the interval in months between the date of
urgical resection and the date of either death or the last follow-up.
he period of disease-free time to recurrence was defined as the
nterval in months between the date of surgical resection and the
ABLE 1. Characteristics of 445 patients with resected
tage I non–small cell lung cancer with a diameter of 3 cm
r less
ariables No. of patients (%)
ge, y (mean  SD) 65.5  9.4
ex
Male 348 (78.2)
Female 97 (21.8)
moking index (pack-y, mean  SD) 23.4 25.2
umor location
Right lung 336 (75.5)
Left lung 109 (24.5)
umor size, cm (mean  SD) 2.25 0.6
istologic type
Adenocarcinoma 226 (50.8)
Squamous cell carcinoma 145 (32.6)
Bronchioalveolar carcinoma 34 (7.6)
Large cell carcinoma 36 (8.1)
Adenosquamous carcinoma 4 (0.9)
xtent of pulmonary resection
Lobectomy or wedge resection 375 (84.3)
Pneumonectomy or bilobectomy 70 (15.7)
isceral pleural invasion
Absent 368 (82.7)
Present 72 (16.2)
o. of LNs dissected (mean  SD) 14.4  10.0
LN  15 262 (58.9)
LN  15 176 (39.6)
o. of LN stations dissected (mean  SD) 3.7  1.7
3 189 (42.5)
3 238 (53.5)
ymphatic invasion
Absent 142 (31.9)
Present 47 (10.6)
ascular invasion
Absent 174 (39.1)
Present 15 (3.4)
D, Standard deviation; LN, lymph node.ate the first site of recurrence was found. For disease-free sur-
and Cardiovascular Surgery ● Volume 134, Number 3 639
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G
TSival, an observation was censored at the last follow-up session
hen the patient was alive or had died of causes other than
SCLC.
The overall survival and disease-free survivals were calculated
y the Kaplan–Meier method.20 Univariate and multivariate anal-
ses were performed by means of the Cox proportional hazards
odel using the Statistical Package for the Social Sciences soft-
are (version 12.0; SPSS Inc, Chicago, Ill). Backward stepwise
egression procedure was used. Data of lymphatic invasion and
ascular invasion were available in only 189 of the 445 patients
42.5%). The 2 variables were only entered into univariate analy-
es and not multivariate analyses.
esults
he median follow-up time was 70.4 months (mean, 78.4
5.8 months; range, 0.2–298.1 months) for the 445 patients
ith surgically resected stage I NSCLC with a diameter of
cm or less. There were 26 patients lost to follow-up. No
atient received adjuvant chemotherapy after surgical resec-
ion. At the last follow-up session, 162 patients were alive
including 5 patients alive with recurrent cancers), 144
atients died of other causes without evidence of tumor
ecurrence, and 103 patients (16.2%) died of cancer. Ten
ostoperative deaths (2.2%) occurred (lobectomy in 6
atients, pneumonectomy in 3 patients, and wedge resection
n 1 patient). Six of these 10 patients died of pneumonia and
ubsequent acute respiratory distress syndrome. There were
o intraoperative deaths. The 5- and 10-year overall surviv-
ls were 61.4% and 40.0%, respectively (Figure 1). The 5-
nd 10-year disease-free survivals were 74.5% and 73.4%,
igure 1. Cumulative probability of overall survival in patients
ith surgically resected stage I NSCLC with a diameter of 3 cm
r less.espectively (Figure 2). s
40 The Journal of Thoracic and Cardiovascular Surgery ● Septeredictors of Disease-free Survival
nivariate analyses showed that smoking index (P  .005),
umor size (P  .003), and number of mediastinal lymph
odes dissected (P  .005) had a significant effect on
isease-free survival (Table 2). The hazard of lung cancer
ecurrence was greater in patients with a higher smoking
ndex, larger tumor size, and smaller number of mediastinal
ymph nodes dissected. VPI was not associated with an
ncreased hazard of cancer recurrence in these patients
Figure 3, A).
Smoking index (P  .002), tumor size (P  .009), and
umber of mediastinal lymph nodes dissected (P  .006)
ere still found to be significant in multivariate analyses
Table 3).
redictors of Overall Survival
nivariate analyses indicated that age (P  .001), gender
P  .001), smoking index (P  .001), tumor size (P 
001), histologic type (P  .001), number of mediastinal
ymph nodes dissected (P  .002), and number of medias-
inal lymph node stations dissected (P  .002) had a sig-
ificant influence on overall survival (Table 2). Survival
as significantly better in women and in younger patients.
he hazard of death was greater in patients with a higher
moking index, larger tumor size, smaller number of medi-
stinal lymph nodes dissected, and smaller number of me-
iastinal lymph node stations dissected. The hazard of death
as greater in patients with squamous cell carcinoma versus
ther histologic types. VPI was not associated with an
ncreased hazard of death in these patients (Figure 3, B).
Only age (P  .005), smoking index (P  .001), tumor
igure 2. Cumulative probability of disease-free survival in pa-
ients with surgically resected stage I NSCLC with a diameter of
cm or less.ize (P  .004), and number of mediastinal lymph nodes
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G
TSissected (P  .001) were still significant prognostic indi-
ators in multivariate analyses (Table 3).
iscussion
his study investigated the prognostic role of conventional
linicopathologic factors in patients with resected stage I
SCLC with a diameter of 3 cm or less. The 5-year overall
urvival and disease-free survivals were 61.4% and 74.5%,
espectively. Tumor size, smoking index, and number of
ediastinal lymph nodes dissected were significant predic-
ors for both disease-free survival and overall survival. Age
as a significant prognostic factor for overall survival only.
ender, extent of pulmonary resection, and VPI did not
nfluence overall survival and disease-free survival. Surgi-
al resection offers a good chance of cure for patients with
tage I NSCLC, with the 5-year survival between 55% and
0%.2-6 Five-year overall survival in resected IA NSCLC
as been reported as reaching 62% to 82%.6-9 Five-year
isease-free survival in resected stage IA NSCLC has been
eported in 75% of cases.8 Our study shows similar results
f overall survival and disease-free survival in patients with
esected stage I NSCLC with a diameter of 3 cm or less.
Tumor size is an important factor in a lung cancer
taging system.6,21-23 Tumor size is a significant prognostic
actor for stage I NSCLC.4,6,16 The prognostic significance
f tumor size in stage IA NSCLC has been controver-
ial.6,8,9,24,25 The use of 2 cm or 3 cm as a cutoff value has
een reported. Patz and colleagues9 reported that there is no
orrelation between tumor size and survival. However,
irim and colleagues7 and Port and colleagues8 reported
umor size as an important predictor of survival in stage IA
ABLE 2. Univariate analyses for overall and disease-free
ancer with a diameter of 3 cm or less
ariables H
ge, y 1.036
ender (male vs female) 1.888
moking index, pack-y* 1.012
ocation (right vs left lung) 0.893
umor size† 1.402
istologic type (squamous cell carcinoma vs others) 1.559
xtent of pulmonary resection (pneumonectomy or
bilobectomy vs lobectomy or wedge resection)
0.967
isceral pleural invasion (present vs absent) 1.016
o. of LNs dissected ( 15 vs  15) 0.656
o. of LN stations dissected ( 3 vs  3) 0.671
ymphatic invasion (present vs absent) 0.811
ascular invasion (present vs absent) 0.525
SCLC, Non–small cell lung cancer; HR, hazard ratio; CI, confidence inte
ncreased hazard per 1 pack-year of additional smoking. †The hazard ratio
-cm increase in tumor size.SCLC, suggesting 2 cm as a cutoff value. For resected a
The Journal of Thoracictage I NSCLC with a diameter of 3 cm or less, our results
emonstrated that tumor size was a significant predictor for
oth disease-free survival and overall survival.
The number of mediastinal lymph nodes dissected af-
ected both disease-free survival and overall survival in
ultivariate analyses in resected stage I NSCLC with a
iameter of 3 cm or less. The number of mediastinal lymph
odes dissected during thoracotomy was used alternatively
o represent the quality of lymphadenectomy in patients
ith resected stage I NSCLC.17 The quality of lymphade-
ectomy had an impact on a more accurate tumor staging
nd significantly affected the survival of patients with stage
 NSCLC.17 Our results show that for resected stage I
SCLC with a diameter of 3 cm or less, patients with 15 or
ewer mediastinal lymph nodes dissected had worse sur-
ival outcome than those with more than 15. However, the
umber of mediastinal lymph node stations dissected influ-
nced neither overall survival nor disease-free survival in
ultivariate analyses.
VPI is an important prognostic factor in patients who
nderwent complete resection of NSCLC.10-13 VPI is also
ssociated with a higher frequency of lymph node involve-
ent.10,11,15 The incidence of VPI in resected NSCLC has
een reported to be between 19.1% and 26.8%.10,11,26 Fur-
hermore, the incidence of VPI has been identified in 18.1%
nd 21.2% of resected stage I NSCLC cases.10,11 The inci-
ence of VPI in T1/2 resected NSCLC with N0 disease was
ower than in those with N1/N2 disease.10,11 In our study,
PI was observed in 16.2% of the resected stage I NSCLC
ases with a diameter of 3 cm or less. Some series demon-
trated VPI as a poor prognostic factor in resected stage I
ivals in patients with resected stage I non–small cell lung
Overall survival Disease-free survival
% CI) P value HR (95% CI) P value
0–1.051) .001 1.009 (0.988–1.029) .410
7–2.647) .001 1.606 (0.968–2.664) .067
8–1.017) .001 1.010 (1.003–1.016) .005
1–1.171) .411 0.836 (0.549–1.274) .404
6–1.714) .001 1.632 (1.177–2.264) .003
4–2.002) .001 1.130 (0.757–1.686) .550
5–1.345) .841 0.939 (0.544–1.621) .822
3–1.130) .776 0.821 (0.577–1.168) .274
4–0.854) .002 0.553 (0.364–0.840) .005
2–0.864) .002 0.713 (0.482–1.053) .089
5–1.252) .343 1.124 (0.546–2.315) .751
4–1.288) .152 0.616 (0.148–2.561) .505
LN, lymph node. *The hazard ratio associated with smoking index is an
ciated with tumor size is that the increase in hazard is associated with asurv
R (95
(1.02
(1.34
(1.00
(0.68
(1.14
(1.21
(0.69
(0.91
(0.50
(0.52
(0.52
(0.21
rval;
assond II NSCLC.4,12,16 Martini and colleagues6 reported that
and Cardiovascular Surgery ● Volume 134, Number 3 641
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G
TSPI did not influence overall survival in resected stage I
SCLC. In Martini and coworkers’ study, they also showed
hat VPI did not influence overall survival in patients with
esected stage I NSCLC with a diameter of 3 cm or less. Our
resent study came to this same conclusion. Further, our
tudy demonstrated that VPI did not influence disease-free
urvival in patients with resected stage I NSCLC with a
iameter of 3 cm or less. There was no significant difference
n overall survival and disease-free survival among patients
ith stage IA and stage IB NSCLC with a tumor size less
han 3 cm. Several recently published trials have suggested
hat adjuvant chemotherapy improves the long-term sur-
igure 3. A, Disease-free survival in patients with resected stage
NSCLC with a diameter of 3 cm or less with or without VPI.
, Overall survival in patients with resected stage I NSCLC with
diameter of 3 cm or less with or without VPI. VPI, Visceral
leural invasion.ival in patients with early-stage NSCLC after a curative
42 The Journal of Thoracic and Cardiovascular Surgery ● Septeesection.27,28 Because patients with resected stage IB
SCLC with a diameter of 3 cm or less have a survival that
s indistinguishable from that of patients with stage IA lung
ancer, it is likely that the benefit of adjuvant chemotherapy
s small or nonexistent in the subset of patients with stage IB
SCLC.
onclusions
umor size, smoking index, and number of mediastinal
ymph nodes dissected were prognostic factors for both
verall survival and disease-free survival in resected stage I
SCLC with a diameter of 3 cm or less. Small tumors (3
m) of stage IB (T2N0M0) NSCLC with VPI should be
reated as T1 disease and not T2 disease. Because the
urrent literature suggests that VPI is associated with a high
ncidence of nodal disease, a full preoperative evaluation to
ule out advanced disease is necessary and would alter the
herapy offered.
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